February 3, 2016

Novo A/S expands its large investment portfolio through investment in Synlab and enters the European central laboratory services industry

Synlab Limited (‘Synlab’ or ‘the Group’), the largest European clinical laboratories company, and Novo A/S (‘Novo’), the holding company for the Novo Group and fully owned subsidiary of the Novo Nordisk Foundation, today announce that Novo has invested in Synlab through the acquisition of an option to buy a stake for more than 10% of the equity of Synlab Group for an undisclosed amount.